Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF R1

VEGF R1

Brief Information

Name:Vascular endothelial growth factor receptor 1
Target Synonym:Fms Related Receptor Tyrosine Kinase 1,EC:2.7.10.1,VEGFR1,Tyrosine-protein kinase receptor FLT,FRT,Fms-like tyrosine kinase 1,FLT1,Vascular Permeability Factor Receptor,Vascular Endothelial Growth Factor Receptor 1,Fms Related Tyrosine Kinase 1,Fms-Related Tyrosine Kinase 1 (Vascular Endothelial Growth Factor/Vascular Permeability Factor Receptor),VEGFR-1,Vascular Endothelial Growth Factor Receptor-1,Tyrosine-Protein Kinase FRT,FLT-1,FLT,Fms-Related Tyrosine Kinase 1,EC 2.7.10.1,EC 2.7.10
Number of Launched Drugs:12
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

VE1-H82E3-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human VEGF R1, His,Avitag (Cat. No. VE1-H82E3) on SA Biosensor, can bind Human VEGF165, His Tag (Cat. No. VE5-H5248) with an affinity constant of 0.236 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

VE1-M5256-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Mouse VEGF164, His,Avitag (Cat. No. VE4-M82Q3) on SA Biosensor, can bind Mouse VEGF R1, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE1-M5256) with an affinity constant of 42.4 pM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

FLT,VEGFR1,FLT1

Background

Vascular endothelial growth factor receptor 1 (VEGFR1) is also known as Fms-like tyrosine kinase 1 (FLT-1), Tyrosine-protein kinase receptor FLT, is a single-pass type I membrane protein and secreted protein which belongs to the protein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily. VEGFR1 is detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues and specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. VEGFR1 acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR1 may play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. VEGFR1 can promote endothelial cell proliferation, survival and angiogenesis in adulthood.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tivozanib AV-951; KRN-951; ASP-4130; Kil-8951 Approved Kyowa Hakko Kirin Co Ltd Fotivda United States Carcinoma, Renal Cell Aveo Pharmaceuticals Inc 2017-08-24 Solid tumours; Carcinoma, Renal Cell; Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung Details
Plitidepsin APLD Approved Pharma Mar Sa Aplidin Australia Multiple Myeloma null 2018-12-11 Leukemia; Coronavirus Disease 2019 (COVID-19); Multiple Myeloma; Prostatic Neoplasms; Primary Myelofibrosis; Lymphoma Details
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Pain; Esophageal Neoplasms; Glioblastoma; Kidney Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Pazopanib Hydrochloride GW-786034; SB-786034; GSK-786034; GW-786034B Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Patorma, Votrient Mainland China Carcinoma, Renal Cell Novartis Pharma Schweiz Ag 2009-10-19 Osteosarcoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Glioma; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Sarcoma; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Hemangiosarcoma; Carcinoma, Renal Cell; Solid tumours; Chondrosarcoma; Telangiectasia, Hereditary Hemorrhagic Details
Axitinib PF-01367866; AG-13736; AG-013736; CLS-AX Approved Pfizer Pharmaceuticals Ltd (China) Inlyta, 英立达 Mainland China Carcinoma, Renal Cell Pfizer Europe Ma Eeig 2012-01-27 Hepatic Insufficiency; Melanoma; Adenocarcinoma; Macular Degeneration; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Leukemia, Myeloid, Acute; Lung Neoplasms; Thyroid Neoplasms; Solid tumours; Endometriosis; Myelodysplastic Syndromes; Skin Neoplasms; Carcinoma, Renal Cell; Carcinoma; Kidney Neoplasms; Ovarian Neoplasms Details
Regorafenib DAST; BAY-73-4506 Approved Bayer Ag Resihance, Stivarga Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Solid tumours; Carcinoma, Renal Cell; Rectal Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Fruquintinib HMPL-013 Approved Hutchison Medipharma Ltd 爱优特, Elunate Mainland China Colorectal Neoplasms Hutchison Huangpu Medicine (Shanghai) Co Ltd 2018-09-04 Solid tumours; Rectal Neoplasms; Esophageal Neoplasms; Colonic Neoplasms; Kidney Diseases; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Lenvatinib Mesylate MK-7902; ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 Japan Endometrial Neoplasms Eisai Co Ltd 2015-02-13 Liver Diseases; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Lymphoma; Thyroid Neoplasms; Endometrial Neoplasms; Hepatic Insufficiency; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Biliary Tract Neoplasms Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef Mainland China Idiopathic Pulmonary Fibrosis Boehringer Ingelheim International Gmbh 2014-10-15 Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Scleroderma, Systemic; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Multiple Myeloma; Prostatic Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Small Cell Lung Carcinoma Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Endometrial Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Sarcoma, Alveolar Soft Part; Gallbladder Neoplasms; Medullary thyroid cancer (MTC); Thyroid Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Osteoma; Carcinoma, Renal Cell; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Thoracic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Genital Diseases, Female; Leiomyosarcoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Neuroendocrine Tumors; Sarcoma; Bile Duct Diseases Details
Sorafenib Tosylate NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 Approved Onyx Pharmaceuticals Inc 多吉美, Nexavar EU Thyroid Neoplasms Bayer Ag 2005-12-01 Breast Neoplasms; Neoplasm Metastasis; Fasting; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Thyroid Neoplasms; Hepatitis C; Hepatitis B; Liver Neoplasms; Liver Diseases; Pancreatic Neoplasms; Kidney Diseases; Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Solid tumours; Ovarian Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive Details
Sunitinib Malate PHA-290940; SU-010398; SU-11248; GB-102; PNU-290940; SU-011248-L-malate salt; PNU-290940AD; PHA-290940AD Approved Pfizer Pharmaceuticals Ltd (China) Sutent, 索坦 Japan Pancreatic neuroendocrine tumors (pNET) Pfizer Inc 2006-01-26 Breast Neoplasms; Retinal Vein Occlusion; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Macular Degeneration; Carcinoma, Hepatocellular; Urogenital Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Diabetic macular oedema; Prostatic Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Urologic Diseases; Kidney Diseases; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Stomach Neoplasms; Carcinoma, Islet Cell; Carcinoma, Renal Cell; Liver Neoplasms; Solid tumours Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Cediranib AZD2171; AZD-2171; NSC-732208 Phase 2 Clinical Astrazeneca Plc Glioblastoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Hepatic Insufficiency; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Biliary Tract Neoplasms; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Liver Neoplasms; Leukemia; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms Details
OCV-101 OCV-101; OTS-11101 Phase 2 Clinical Oncotherapy Science Pancreatic Neoplasms Details
VEGFR-1/2 peptide vaccine (Keio University) Phase 2 Clinical Keio University Neurofibromatoses; Brain Neoplasms; Glioma Details
Glesatinib MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly Phase 2 Clinical Mirati Therapeutics Carcinoma, Non-Small-Cell Lung Details
Icrucumab 18-F-1; IMC-18-F-1; LY-3012212 Phase 2 Clinical Imclone Systems, Eli Lilly And Company Solid tumours; Rectal Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Breast Neoplasms; Urethral Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Ureteral Neoplasms; Urogenital Neoplasms Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Thymus Neoplasms; Genital Neoplasms, Female; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Sitravatinib MG-516; MG-91516; MGCD-516; IND-155305 Phase 3 Clinical Mirati Therapeutics Solid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Hepatic Insufficiency; Ureteral Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular Details
Hydroxychloroquine/Sorafenib Phase 1 Clinical Vg Life Sciences Ovarian Neoplasms Details
Chiauranib CS-2164 Phase 3 Clinical Shenzhen Chipscreen Biosciences Co Ltd Solid tumours; Ovarian Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular Details
Famitinib Malate SHR-1020 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Fallopian Tube Neoplasms; Urogenital Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Gastrointestinal Stromal Tumors; Ovarian Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Nasopharyngeal Carcinoma; Idiopathic Pulmonary Fibrosis; Nasopharyngeal Neoplasms; Carcinoma, Transitional Cell; Pancreatic neuroendocrine tumors (pNET); Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours Details
MG-D-1609 MG-D-1609 Phase 2 Clinical Metagone Biotech Solid tumours Details
Sorafenib/MG-005 MGD-1509; MG-D-1509 Phase 1 Clinical Metagone Biotech, Tri-Service General Hospital Solid tumours Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message